Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations);Uso de boceprevir y telaprevir en pacientes con VHC (aspectos prácticos)

Gastroenterologia y Hepatologia

Volumn 35, Issue 5, 2012, Pages 337-343

  Crespo, Gonzalo ^a   Lens, Sabela ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Adverse effects; Drug interactions; Hepatitis C; Protease inhibitors

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; PRACTICE GUIDELINE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84860240704     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.12.005     Document Type: Article

References (22)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
2. Vezali E., Aghemo A., Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010, 32:2117-2138.
3. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
4. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
5. Telaprevir (Incivo®). Información de producto. Disponible en http://www.ema.europa.eu/.
6. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
7. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
8. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
9. Boceprevir (Victrelis®). Información de producto. Disponible en http://www.ema.europa.eu/.
10. Mistry N., Shapero J., Crawford R.I. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol 2009, 23:677-683.
11. Cacoub P., Bourliere M., Lubbe J., Dupin N., Buggisch P., Dusheiko G., et al. Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. J Hepatol 2011, (ePub).
12. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
13. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.A., Jacobson I.M., Afdhal N.H., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
14. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
15. Cacoub P., Musette P., Descamps V., Meyer O., Speirs C., Finzi L., et al. The DRESS syndrome: a literature review. Am J Med 2011, 124:588-597.
16. Worswick S., Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther 2011, 24:207-218.
17. Sherman K.E., Flamm S.L., Afdhal N.H., Nelson D.R., Sulkowski M.S., Everson G.T., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-1024.
18. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
19. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
20. Susser S., Vermehren J., Forestier N., Welker M.W., Grigorian N., Fuller C., et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011, 52:321-327.
21. Kwo P.Y., Zhao R. Boceprevir: a user's guide. Clin Liver Dis 2011, 15:537-553.
22. Muir A.J. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther 2011, 9:1105-1114.